Form 10-K

Overview

The report describes Capricor as a clinical-stage biotechnology company developing cell- and exosome-based therapeutics. During 2021, it reported final 12-month HOPE-2 results showing improvements in upper-limb and cardiac function, and completed enrollment of 63 patients in its INSPIRE Phase II COVID-19 trial. The company reported 48 full-time employees and total revenue of $244,898 for 2021 while initiating the HOPE-3 Phase III DMD study.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2021
Period: Ends 31 December 2021
Publication date: 11 March 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services